{ "issue_id": "SS-OUTLOOK-2026-10-EXECUTION-TRANSITION", "version": "1.0.0", "status": "published", "evidence_cutoff": "2026-10-21", "dataset_version": "1.0.21", "dataset_file_sha256": "105564f84d9fe798ca3a1a10f645aa8e5934837ac76df2b20d88a297eeb95f57", "issue_file_sha256": "f26964b55bbffdd4a39d891b252851614338d5b0482eea30438957a3979595e7", "approved_ids": [ "SS-AIDT-2025-0001", "SS-AIDT-2026-0004", "SS-AIDT-2026-0007", "SS-AIDT-2025-0002", "SS-AIDT-2026-0008", "SS-AIDT-2026-0009", "SS-AIDT-2026-0010", "SS-AIDT-2026-0011", "SS-AIDT-2026-0012", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016", "SS-AIDT-2026-0018", "SS-AIDT-2026-0017", "SS-AIDT-2026-0019" ], "approved_count": 16, "excluded_provisional_count": 5, "current_period_announcement_ids": [ "SS-AIDT-2026-0018", "SS-AIDT-2026-0017", "SS-AIDT-2026-0019" ], "historical_baseline_ids": [ "SS-AIDT-2025-0001", "SS-AIDT-2026-0004", "SS-AIDT-2026-0007", "SS-AIDT-2025-0002", "SS-AIDT-2026-0008", "SS-AIDT-2026-0009", "SS-AIDT-2026-0010", "SS-AIDT-2026-0011", "SS-AIDT-2026-0012", "SS-AIDT-2026-0013", "SS-AIDT-2026-0014", "SS-AIDT-2026-0015", "SS-AIDT-2026-0016" ], "industry_mix": { "Biomedical research, life sciences, drug discovery, scientific AI, and public research infrastructure": 1, "Biopharmaceutical research, antibody engineering, and scientific AI": 1, "Biotechnology, scientific AI, and AI infrastructure": 1, "Cybersecurity & critical infrastructure": 1, "Energy & geoscience": 1, "Healthcare, medical imaging and clinical AI": 1, "Healthcare, oncology, biotechnology and AI drug discovery": 1, "Healthcare, precision medicine and clinical AI": 1, "Legal technology, enterprise contracting, procurement, and frontier AI": 1, "News publishing, digital media, search and generative AI": 1, "Pharmaceuticals & biotechnology": 2, "Semiconductor design, electronic design automation, and frontier AI": 1, "Software development & AI training data": 1, "Voice AI & training data": 2 }, "structure_mix": { "Federated / Controlled Learning Rights": 3, "Proprietary Corpus License": 3, "Strategic Model Co-Development": 3, "Training Rights License": 7 }, "corpus_renewal": { "Finite Corpus": 2, "Renewable Corpus": 13, "unknown": 1 }, "asset_disposition": { "Embedded / Continuing": 14, "Stranded / Separable": 2 }, "median_asset_score": 86, "median_signal_score": 68, "scores_are_analyst_judgments": true, "combined_transaction_dollars": null, "valuation_range": null, "pricing_observations": [ { "transaction_id": "SS-AIDT-2025-0001", "amount": null, "currency": null, "description": "No data-specific consideration disclosed.", "status": "not_disclosed", "economics_scope": "not_disclosed" }, { "transaction_id": "SS-AIDT-2026-0004", "amount": null, "currency": null, "description": "Government GPU support is disclosed, alongside consortium computing resources. Dataset-specific cash consideration is not disclosed.", "status": "in_kind_and_government_compute", "economics_scope": "bundled_program_support" }, { "transaction_id": "SS-AIDT-2026-0007", "amount": 100000000, "amount_qualifier": "greater_than", "currency": "EUR", "description": "More than €100 million over three years; explicitly a program-wide investment, not a dataset price.", "status": "disclosed_program_commitment", "economics_scope": "bundled_research_compute_people_and_implementation" }, { "transaction_id": "SS-AIDT-2025-0002", "amount": 200000000, "currency": "USD", "description": "$200m data-license fees over three years, including $50m upfront payable. Up to 50% may be settled in Pathos preferred shares. Separate $35m flows run from AstraZeneca to Tempus and Tempus to Pathos.", "status": "disclosed_contractual_fees_not_verified_cash_receipts", "economics_scope": "contractually_identified_data_license_fees_within_broader_arrangement" }, { "transaction_id": "SS-AIDT-2026-0008", "status": "disclosed_non_cash_user_consideration", "amount": null, "currency": null, "description": "Individual Pro users receive up to 50× additional Forge usage during the preview; Bolt describes the allocation as payment for sharing. Bolt may also receive cash for licensed datasets, but no amount is disclosed.", "economics_scope": "In-kind usage allocation to contributing users; any Arcee-to-Bolt license payment is undisclosed." }, { "transaction_id": "SS-AIDT-2026-0009", "status": "disclosed_contract_value", "amount": 250000, "currency": "USD", "description": "Dataset-specific contract value disclosed as $250,000; the buyer is unnamed.", "economics_scope": "Specific Tagalog and Cebuano single- and multi-speaker voice-data contract." }, { "transaction_id": "SS-AIDT-2026-0010", "status": "not_disclosed", "amount": null, "currency": null, "description": "The announcement discloses the license but not its consideration.", "economics_scope": "Separate license for five African-language datasets; no transaction economics are disclosed." }, { "transaction_id": "SS-AIDT-2026-0011", "status": "disclosed_revenue_share_structure_amount_not_disclosed", "amount": null, "currency": null, "description": "Harell states that data owners receive a revenue share on every training job executed against their dataset; the percentage, minimum commitment, and cash amount are not disclosed. Model builders can also collect a fee when users run marketplace-listed models.", "economics_scope": "Per-training-run data-owner revenue share and usage fees for downstream Models as a Service; CoreWeave contract value and exact revenue-share percentages are not disclosed." }, { "transaction_id": "SS-AIDT-2026-0012", "status": "disclosed_contractual_license_fees", "amount": 42000000, "currency": "USD", "description": "The 2026 amendment sets $14 million annual license fees on each of the third, fourth and fifth anniversaries, at least $4 million of each payable in cash and the remainder in cash and/or Recursion shares. The original 2023 deal disclosed up to $160 million over five years.", "economics_scope": "$42 million of amended third-through-fifth anniversary license fees is explicitly disclosed; amounts already paid under the original schedule and the economic effect of the reduced unique-record cap are not restated here." }, { "transaction_id": "SS-AIDT-2026-0013", "status": "not_disclosed", "amount": null, "currency": null, "description": "The renewed agreement's financial consideration, minimum commitments and pricing formula are not disclosed.", "economics_scope": "No agreement value, per-study pricing, revenue share, equity component or other economic terms are disclosed." }, { "transaction_id": "SS-AIDT-2026-0014", "status": "reported_range_only", "amount": null, "currency": null, "description": "Seven-figure multiyear agreement, plus incremental annual sublicensing revenue to OneMedNet for each downstream end-customer license; exact contract value, currency, payment form, annual schedule and per-license revenue share are not disclosed in the reviewed issuer announcement.", "economics_scope": "The disclosed seven-figure amount applies to the multiyear data license. OneMedNet separately states that it receives recurring sublicensing revenue on each downstream license of the derivative product and that the agreement includes an option to expand data volume and contract value; exact values are not disclosed." }, { "transaction_id": "SS-AIDT-2026-0015", "status": "not_disclosed", "amount": null, "currency": null, "description": "No membership fee, cash consideration, revenue share, minimum commitment, or asset valuation is disclosed. Members contribute proprietary sequences and receive governed access to consortium data, models, and derivatives for internal use.", "economics_scope": "Member contributions, assay generation, model-development services, and internal-use benefits are disclosed; transaction value and the allocation of consideration among data, laboratory work, infrastructure, and models are not disclosed." }, { "transaction_id": "SS-AIDT-2026-0016", "status": "economic_structure_disclosed_amount_not_disclosed", "amount": null, "currency": null, "description": "Reuters reports that OpenAI pays Synopsys a training subscription fee and that the parties share downstream GPT-Synopsys revenue. Dollar amounts, revenue-share percentages, minimum commitments, and term-by-term allocation are not disclosed.", "economics_scope": "The reported training subscription covers development access, while downstream revenue sharing covers commercial use. The reviewed sources do not allocate value among tools, expertise, workflow access, model hosting, or go-to-market rights." }, { "transaction_id": "SS-AIDT-2026-0018", "status": "aggregate_commitments_disclosed_allocation_partial", "amount": 1800000000, "currency": "USD", "description": "The initiative totals $1.8 billion in funding, data, compute and measurement technology: $300 million jointly from Meta, Google DeepMind and Isomorphic Labs, more than $500 million from DOE over five years, more than $500 million in prior NIH-funded resources, and Biohub’s earlier $500 million commitment.", "economics_scope": "Only the $300 million commercial contribution is directly associated with the time-limited embargo advantage; the disclosed $1.8 billion total also includes public and philanthropic investments and in-kind resources." }, { "transaction_id": "SS-AIDT-2026-0017", "status": "not_disclosed", "amount": null, "currency": null, "description": "No cash consideration or commercial rights allocation is disclosed; the material consideration is expert workflow design, hosted product access and model-development collaboration.", "economics_scope": "The announcement does not allocate value among expert time, hosted environments, synthetic task creation, evaluation design or prospective product integration." }, { "transaction_id": "SS-AIDT-2026-0019", "status": "paid_terms_undisclosed", "amount": null, "currency": null, "description": "Google states that it pays participating publications for content delivery and use; CNN confirms compensation. Financial amounts and publisher-level allocations are not disclosed.", "economics_scope": "Payment is expressly associated with enhanced-content delivery and use in the AI pilot, but amounts, rate structure and allocations across more than 400 publications are not disclosed." } ], "measured_uplift": [ { "transaction_id": "SS-AIDT-2025-0001", "baseline": "OpenFold3 Preview 2", "evaluation_n": 1056, "evidence_status": "consortium_reported_not_independently_replicated", "limitations": "Private held-out evaluation; consortium-funded work; clinical utility and independent replication not established.", "metrics": [ { "baseline_pct": 35.6, "change_percentage_points": 16.5, "name": "fraction PL-lDDT >= 0.8", "updated_pct": 52.1 }, { "baseline_pct": 28.9, "change_percentage_points": 17.9, "name": "fraction ligand bisyRMSD <= 2 angstrom", "updated_pct": 46.8 } ], "reported_on": "2026-09-14", "training_structures": 20167 } ], "forecast_count": 4, "context_registry": { "archive_path": "data/ai-access-history/000012.json", "archive_sha256": "c9e2ac850b330d1fb0c2d8392f2393e13713679edfa8fb45c7fa068836cd4c7f", "registry_sha256": "fd2fcbf4951e41e391a0dc6a718b2abbb485052903a2ac9b451f2807a72fc8af", "archived_at": "2026-10-21T15:12:37.406Z", "ontology_version": "2.0.0", "canonical_count": 119, "human_reviewed_count": 114, "provisional_count": 5, "strict_data_rights_flag_count": 21, "strict_data_rights_human_reviewed_count": 16, "data_rights_version": "1.0.21", "capability_catalog_version": "1.0.101" }, "access_facet_counts": { "total": 119, "reviewed": 114, "provisional": 5, "strict_rights": 21, "reviewed_strict": 16, "knowledge": 119, "professional_workflow": 85, "action_execution": 78, "retrieval": 100, "ongoing_feed": 56, "human_response": 8, "training": 14 }, "registry_delta": { "from_archive_path": "data/ai-access-history/000006.json", "from_archive_sha256": "29c5dc15e5ed50dc504cc6938e5475f82d03f9e2bd011dc9d005aefb874b0d64", "counts": { "previous_count": 88, "newly_recorded": 31, "new_professional_workflow": 29, "new_action_execution": 27, "new_retrieval": 31, "new_ongoing_feed": 23, "new_strict_rights": 1, "newly_recorded_with_october_announcement": 30 } } }